{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T03:51:21Z","timestamp":1778557881371,"version":"3.51.4"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81373337"],"award-info":[{"award-number":["81373337"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Basic Research Program of China","doi-asserted-by":"crossref","award":["2013CB932504"],"award-info":[{"award-number":["2013CB932504"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"name":"State Key Program of National Natural Science of China","award":["81130060"],"award-info":[{"award-number":["81130060"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.jconrel.2014.10.017","type":"journal-article","created":{"date-parts":[[2014,10,24]],"date-time":"2014-10-24T18:29:33Z","timestamp":1414175373000},"page":"324-331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Enhanced antitumor and anti-metastasis efficiency via combined treatment with CXCR4 antagonist and liposomal doxorubicin"],"prefix":"10.1016","volume":"196","author":[{"given":"Ling","family":"Mei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yayuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huile","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhirong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jconrel.2014.10.017_bb0005","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.cell.2011.09.024","article-title":"Tumor metastasis: molecular insights and evolving paradigms","volume":"147","author":"Valastyan","year":"2011","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.jconrel.2014.10.017_bb0010","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.cell.2006.11.001","article-title":"Cancer metastasis: building a framework","volume":"127","author":"Gupta","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2014.10.017_bb0015","series-title":"Oncologic Therapies","first-page":"19","author":"Ewesuedo","year":"2003"},{"issue":"5","key":"10.1016\/j.jconrel.2014.10.017_bb0020","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1021\/mp100171c","article-title":"Efficient delivery of payload into tumor cells in a controlled manner by TAT and thiolytic cleavable PEG co-modified liposomes","volume":"7","author":"Kuai","year":"2010","journal-title":"Mol. Pharm."},{"issue":"0","key":"10.1016\/j.jconrel.2014.10.017_bb0025","first-page":"1","article-title":"Liposomes co-modified with cholesterol anchored cleavable PEG and octaarginines for tumor targeted drug delivery","author":"Tang","year":"2014","journal-title":"J. Drug Target."},{"issue":"17","key":"10.1016\/j.jconrel.2014.10.017_bb0030","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1016\/j.biomaterials.2014.02.031","article-title":"Paclitaxel loaded liposomes decorated with a multifunctional tandem peptide for glioma targeting","volume":"35","author":"Liu","year":"2014","journal-title":"Biomaterials"},{"issue":"2","key":"10.1016\/j.jconrel.2014.10.017_bb0035","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0169-409X(95)00029-7","article-title":"Pharmacokinetics of long-circulating liposomes","volume":"16","author":"Allen","year":"1995","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"8","key":"10.1016\/j.jconrel.2014.10.017_bb0040","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/nm1469","article-title":"Tumor metastasis: mechanistic insights and clinical challenges","volume":"12","author":"Steeg","year":"2006","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.jconrel.2014.10.017_bb0045","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nrc2256","article-title":"Models, mechanisms and clinical evidence for cancer dormancy","volume":"7","author":"Aguirre-Ghiso","year":"2007","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.jconrel.2014.10.017_bb0050","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","article-title":"Epithelial-mesenchymal transitions in development and disease","volume":"139","author":"Thiery","year":"2009","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.jconrel.2014.10.017_bb0055","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0959-8049(01)00086-7","article-title":"Selection with melphalan or paclitaxel (Taxol) yields variants with different patterns of multidrug resistance, integrin expression and < i > in vitro invasiveness","volume":"37","author":"Liang","year":"2001","journal-title":"Eur. J. Cancer"},{"issue":"8","key":"10.1016\/j.jconrel.2014.10.017_bb0060","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.addr.2011.04.008","article-title":"Targeting tumor cell motility to prevent metastasis","volume":"63","author":"Palmer","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"7","key":"10.1016\/j.jconrel.2014.10.017_bb0065","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrc1388","article-title":"Cancer and the chemokine network","volume":"4","author":"Balkwill","year":"2004","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.jconrel.2014.10.017_bb0070","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1182\/blood-2005-08-3182","article-title":"CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment","volume":"107","author":"Burger","year":"2006","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.jconrel.2014.10.017_bb0075","first-page":"3833","article-title":"The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases","volume":"63","author":"Zeelenberg","year":"2003","journal-title":"Cancer Res."},{"issue":"20","key":"10.1016\/j.jconrel.2014.10.017_bb0080","first-page":"5930","article-title":"Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer","volume":"62","author":"Scotton","year":"2002","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.jconrel.2014.10.017_bb0085","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1158\/1078-0432.CCR-04-1887","article-title":"Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma","volume":"11","author":"Scala","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.jconrel.2014.10.017_bb0090","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/leu.2008.299","article-title":"CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers","volume":"23","author":"Burger","year":"2009","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.jconrel.2014.10.017_bb0095","doi-asserted-by":"crossref","first-page":"e74548","DOI":"10.1371\/journal.pone.0074548","article-title":"Preclinical development of a novel class of CXCR4 antagonist impairing solid tumors growth and metastases","volume":"8","author":"Portella","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jconrel.2014.10.017_bb0100","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1023\/A:1006633616629","article-title":"Enhanced inhibition of experimental metastasis by the combination chemotherapy of Cu\u2013Zn SOD and adriamycin","volume":"17","author":"Kogawa","year":"1999","journal-title":"Clin. Exp. Metastasis"},{"issue":"18","key":"10.1016\/j.jconrel.2014.10.017_bb0105","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.1182\/blood-2008-10-186668","article-title":"CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy","volume":"113","author":"Azab","year":"2009","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jconrel.2014.10.017_bb0110","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1593\/neo.12324","article-title":"CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy","volume":"14","author":"Domanska","year":"2012","journal-title":"Neoplasia"},{"issue":"7","key":"10.1016\/j.jconrel.2014.10.017_bb0115","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1021\/mp500057n","article-title":"Synergistic dual-ligand doxorubicin liposomes improve targeting and therapeutic efficacy of brain glioma in animals","volume":"11","author":"Zong","year":"2014","journal-title":"Mol. Pharm"},{"issue":"5","key":"10.1016\/j.jconrel.2014.10.017_bb0120","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.biomaterials.2012.10.057","article-title":"Simultaneous inhibition of metastasis and growth of breast cancer by co-delivery of twist shRNA and paclitaxel using pluronic P85-PEI\/TPGS complex nanoparticles","volume":"34","author":"Shen","year":"2013","journal-title":"Biomaterials"},{"issue":"11","key":"10.1016\/j.jconrel.2014.10.017_bb0125","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1158\/1078-0432.CCR-09-2329","article-title":"CXCL12 (SDF-1)\/CXCR4 pathway in cancer","volume":"16","author":"Teicher","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.jconrel.2014.10.017_bb0130","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1021\/mp3005808","article-title":"Efficient simultaneous tumor targeting delivery of all-trans retinoid acid and paclitaxel based on hyaluronic acid-based multifunctional nanocarrier","volume":"10","author":"Yao","year":"2013","journal-title":"Mol. Pharm."},{"issue":"7","key":"10.1016\/j.jconrel.2014.10.017_bb0135","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1158\/1541-7786.MCR-06-0368","article-title":"Involvement of an autocrine stromal cell-derived factor-1\/CXCR4 system on the distant metastasis of human oral squamous cell carcinoma","volume":"5","author":"Uchida","year":"2007","journal-title":"Mol. Cancer Res."},{"issue":"1","key":"10.1016\/j.jconrel.2014.10.017_bb0140","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1476-4598-3-29","article-title":"CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer","volume":"3","author":"Mori","year":"2004","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.jconrel.2014.10.017_bb0150","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jdermsci.2004.03.002","article-title":"Chemokine receptors and melanoma metastasis","volume":"36","author":"Murakami","year":"2004","journal-title":"J. Dermatol. Sci."},{"issue":"6824","key":"10.1016\/j.jconrel.2014.10.017_bb0155","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/35065016","article-title":"Involvement of chemokine receptors in breast cancer metastasis","volume":"410","author":"M\u00fcller","year":"2001","journal-title":"Nature"},{"issue":"24","key":"10.1016\/j.jconrel.2014.10.017_bb0165","first-page":"7328","article-title":"Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells","volume":"62","author":"Murakami","year":"2002","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.jconrel.2014.10.017_bb0170","first-page":"413","article-title":"Combination of theanine with doxorubicin inhibits hepatic metastasis of M5076 ovarian sarcoma","volume":"5","author":"Sugiyama","year":"1999","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.jconrel.2014.10.017_bb0175","first-page":"715","article-title":"Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma","volume":"56","author":"Anderson","year":"1996","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.jconrel.2014.10.017_bb0180","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0169-409X(95)00030-B","article-title":"Liposome circulation time and tumor targeting: implications for cancer chemotherapy","volume":"16","author":"Gabizon","year":"1995","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"35","key":"10.1016\/j.jconrel.2014.10.017_bb0185","doi-asserted-by":"crossref","first-page":"8740","DOI":"10.1002\/anie.201203463","article-title":"Dual-function CXCR4 antagonist polyplexes to deliver gene therapy and inhibit cancer cell invasion","volume":"51","author":"Li","year":"2012","journal-title":"Angew. Chem. Int. Ed."},{"issue":"9","key":"10.1016\/j.jconrel.2014.10.017_bb0195","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1158\/1078-0432.CCR-07-2223","article-title":"The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance","volume":"14","author":"Meads","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.jconrel.2014.10.017_bb0200","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/sj.leu.2402924","article-title":"Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms","volume":"17","author":"Nefedova","year":"2003","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.jconrel.2014.10.017_bb0205","first-page":"357","article-title":"The ability in adhesion and invasion of drug-resistant human glioma cells","volume":"19","author":"Hikawa","year":"2000","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.jconrel.2014.10.017_bb0210","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1023\/A:1013880326925","article-title":"Stromal extracellular matrix reduces chemotherapy-induced apoptosis in colon cancer cell lines","volume":"19","author":"Kouniavsky","year":"2002","journal-title":"Clin. Exp. Metastasis"},{"issue":"9","key":"10.1016\/j.jconrel.2014.10.017_bb0215","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/nm909","article-title":"Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia","volume":"9","author":"Matsunaga","year":"2003","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.jconrel.2014.10.017_bb0220","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/nm1483","article-title":"Targeting of CD44 eradicates human acute myeloid leukemic stem cells","volume":"12","author":"Jin","year":"2006","journal-title":"Nat. Med."},{"issue":"24","key":"10.1016\/j.jconrel.2014.10.017_bb0225","doi-asserted-by":"crossref","first-page":"6215","DOI":"10.1182\/blood-2008-05-158311","article-title":"Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML","volume":"113","author":"Zeng","year":"2009","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jconrel.2014.10.017_bb0230","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","article-title":"AKT\/PKB signaling: navigating downstream","volume":"129","author":"Manning","year":"2007","journal-title":"Cell"},{"issue":"41","key":"10.1016\/j.jconrel.2014.10.017_bb0235","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1038\/onc.2008.245","article-title":"PI3K pathway alterations in cancer: variations on a theme","volume":"27","author":"Yuan","year":"2008","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.jconrel.2014.10.017_bb0240","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.molonc.2012.07.001","article-title":"Inhibition of doxorubicin-induced HER3\u2013PI3K\u2013AKT signalling enhances apoptosis of ovarian cancer cells","volume":"6","author":"Bezler","year":"2012","journal-title":"Mol. Oncol."},{"issue":"13","key":"10.1016\/j.jconrel.2014.10.017_bb0245","doi-asserted-by":"crossref","first-page":"6325","DOI":"10.1158\/0008-5472.CAN-06-4261","article-title":"AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin\/p70S6K1 pathway","volume":"67","author":"Liu","year":"2007","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.jconrel.2014.10.017_bb0250","doi-asserted-by":"crossref","first-page":"R589","DOI":"10.1186\/bcr1259","article-title":"Differential responses to doxorubicin-induced phosphorylation and activation of Akt in human breast cancer cells","volume":"7","author":"Li","year":"2005","journal-title":"Breast Cancer Res."},{"issue":"10","key":"10.1016\/j.jconrel.2014.10.017_bb0255","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.4049\/jimmunol.169.10.5546","article-title":"G protein-coupled chemokine receptors induce both survival and apoptotic signaling pathways","volume":"169","author":"Vlahakis","year":"2002","journal-title":"J. Immunol."}],"updated-by":[{"DOI":"10.1016\/j.jconrel.2025.01.043","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000}}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365914007159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365914007159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T07:07:44Z","timestamp":1589267264000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365914007159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":48,"alternative-id":["S0168365914007159"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2014.10.017","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhanced antitumor and anti-metastasis efficiency via combined treatment with CXCR4 antagonist and liposomal doxorubicin","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2014.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}